UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2002
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 0-21185
AAIPHARMA INC.
(Exact name of Registrant as specified in its charter)
DELAWARE 04-2687849
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
2320 SCIENTIFIC PARK DRIVE, WILMINGTON, NC 28405
(Address of principal executive office) (Zip code)
(910) 254-7000
(Registrant's telephone number, including area code)
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. YES [X] NO [ ]
The number of shares of the Registrant's common stock outstanding, as of August
6, 2002 was 18,274,149 shares.
AAIPHARMA INC.
Table of Contents
The terms "Company", "Registrant" or "aaiPharma" in this Form 10-Q include
aaiPharma Inc. and its subsidiaries, except where the context may indicate
otherwise. Any item which is not applicable or to which the answer is negative
has been omitted.
We own the U.S. rights to the following registered and unregistered trademarks:
M.V.I.(R), Aquasol(TM), Brethine(R), Darvon(R), Darvocet-N(R), ProSorb(R),
ProSorb-D(TM), NeoSan(TM) and aaiPharma(TM). We also reference trademarks owned
by other companies. Prilosec(R) is a registered trademark of AstraZeneca AB and
Prozac(R) is a registered trademark of Eli Lilly and Company. All references in
this Form 10-Q to any of these terms lacking the "(R)" or "(TM)" symbols are
defined terms that reference the products, technologies or businesses bearing
the trademarks with these symbols.
Page No.
--------
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS (unaudited)
Consolidated Statements of Operations 3
Consolidated Balance Sheets 4
Consolidated Statements of Cash Flows 5
Consolidated Statements of Comprehensive Income 6
Notes to Consolidated Financial Statements 7
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS 22
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK 30
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS 31
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS 32
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K 32
SIGNATURES 34
EXHIBIT INDEX 35
2
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
AAIPHARMA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
Three Months Ended Six Months Ended
June 30, June 30,
------------------------ ------------------------
2002 2001 2002 2001
--------- --------- --------- ---------
Net revenues $ 61,447 $ 29,884 $ 107,067 $ 60,081
--------- --------- --------- ---------
Operating costs and expenses:
Direct costs 22,061 15,276 44,285 30,725
Selling 5,759 2,891 10,076 5,729
General and administrative 11,703 6,382 21,246 14,125
Research and development 5,596 1,766 10,073 4,108
Direct pharmaceutical start-up costs -- 1,037 -- 1,681
--------- --------- --------- ---------
45,119 27,352 85,680 56,368
--------- --------- --------- ---------
Income from operations 16,328 2,532 21,387 3,713
Other income (expense)
Interest, net (6,553) (327) (8,376) (710)
Other 69 (963) 203 (687)
--------- --------- --------- ---------
(6,484) (1,290) (8,173) (1,397)
--------- --------- --------- ---------
Income before income taxes and extraordinary loss 9,844 1,242 13,214 2,316
Provision for income taxes 3,740 228 5,021 486
--------- --------- --------- ---------
Income before extraordinary loss 6,104 1,014 8,193 1,830
Extraordinary loss, net of a tax benefit of $2,714 -- -- (5,339) --
--------- --------- --------- ---------
Net income $ 6,104 $ 1,014 $ 2,854 $ 1,830
========= ========= ========= =========
Basic earnings (loss) per share
Income before extraordinary loss $ 0.33 $ 0.06 $ 0.45 $ 0.10
Extraordinary loss
-- -- (0.29) --
--------- --------- --------- ---------
Net income $ 0.33 $ 0.06 $ 0.16 $ 0.10
========= ========= ========= =========
Weighted average shares outstanding 18,243 17,721 18,157 17,687
========= ========= ========= =========
Diluted earnings (loss) per share
Income before extraordinary loss $ 0.32 $ 0.06 $ 0.43 $ 0.10
Extraordinary loss
-- -- (0.28) --
--------- --------- --------- ---------
Net income $ 0.32 $ 0.06 $ 0.15 $ 0.10
========= ========= ========= =========
Weighted average shares outstanding 19,043 18,177 19,053 17,936
========= ========= ========= =========
The accompanying notes are an integral part of these financial statements.
3
AAIPHARMA INC.
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
June 30, December 31,
2002 2001
--------- ------------
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 4,212 $ 6,371
Accounts receivable, net 40,341 26,594
Work-in-progress 11,676 10,464
Inventories 9,393 9,057
Prepaid and other current assets 5,863 5,972
--------- ---------
Total current assets 71,485 58,458
Property and equipment, net 52,425 37,035
Goodwill and other intangibles, net 300,525 88,504
Other assets 18,942 12,289
--------- ---------
Total assets $ 443,377 $ 196,286
========= =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current maturities of long-term debt and short-term debt $ 5,417 $ --
Accounts payable 15,601 15,444
Customer advances 17,070 13,349
Accrued wages and benefits 4,315 3,879
Interest payable 6,616 371
Other accrued liabilities 4,936 4,922
--------- ---------
Total current liabilities 53,955 37,965
Long-term debt, less current portion 304,492 78,878
Other liabilities 1,343 224
Commitments and contingencies -- --
Redeemable warrants -- 2,855
Stockholders' equity:
Common stock 18 18
Paid-in capital 78,265 75,233
Retained earnings 6,132 3,278
Accumulated other comprehensive losses (828) (2,165)
--------- ---------
Total stockholders' equity 83,587 76,364
--------- ---------
Total liabilities and stockholders' equity $ 443,377 $ 196,286
========= =========
The accompanying notes are an integral part of these financial statements.
4
AAIPHARMA INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(UNAUDITED)
Six Months Ended
June 30,
---------------------------
2002 2001
--------- ---------
Cash flows from operating activities:
Income before extraordinary loss $ 8,193 $ 1,830
Adjustments to reconcile income before extraordinary loss to
net cash (used in) provided by operating activities
Depreciation and amortization 4,472 3,588
Other 117 869
Changes in operating assets and liabilities:
Trade and other receivables (13,427) (4,758)
Work-in-progress (761) (1,398)
Inventories (275) 800
Prepaid and other assets (12,970) 386
Accounts payable (32) (1,116)
Customer advances 3,413 285
Interest payable 6,245 (64)
Accrued wages and benefits and other accrued liabilities (104) 279
--------- ---------
Net cash (used in) provided by operating activities (5,129) 701
--------- ---------
Cash flows from investing activities:
Purchases of property and equipment (4,402) (2,561)
Purchases of property and equipment previously leased (14,145) --
Proceeds from sales of property and equipment -- 3,050
Acquisitions --
(211,997) --
Other (151) (104)
--------- ---------
Net cash (used in) provided by investing activities (230,695) 385
--------- ---------
Cash flows from financing activities:
Net payments on short-term borrowings -- (1,102)
Proceeds from long-term borrowings 248,755 --
Payments on long-term borrowings (18,400) (336)
Issuance of common stock 3,031 1,115
Other 170 13
--------- ---------
Net cash provided by (used in) financing activities 233,556 (310)
--------- ---------
Net (decrease) increase in cash and cash equivalents (2,268) 776
Effect of exchange rate changes on cash 109 (8)
Cash and cash equivalents, beginning of period 6,371 1,225
--------- ---------
Cash and cash equivalents, end of period $ 4,212 $ 1,993
========= =========
Supplemental information, cash paid for:
Interest $ 2,547 $ 562
========= =========
Income taxes $ 1,947 $ 9
========= =========
The accompanying notes are an integral part of these financial statements.
5
AAIPHARMA INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(IN THOUSANDS)
(UNAUDITED)
Three Months Ended Six Months Ended
June 30, June 30,
------- ----------- -------------------
2002 2001 2002 2001
------- ------- ------- -------
Net income $ 6,104 $ 1,014 $ 2,854 $ 1,830
Currency translation adjustments 1,512 (315) 1,337 (1,080)
Reclassification adjustment of realized loss
on available for sale securities -- 523 -- 591
------- ------- ------- -------
Comprehensive income $ 7,616 $ 1,222 $ 4,191 $ 1,341
======= ======= ======= =======
The accompanying notes are an integral part of these financial statements.
6
AAIPHARMA INC.
Notes to Consolidated Financial Statements
(Unaudited)
1. BASIS OF PRESENTATION
The accompanying unaudited consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States
and applicable Securities and Exchange Commission regulations for interim
financial information. These financial statements do not include all of the
information and footnotes required by accounting principles generally accepted
in the United States for annual financial statements. The consolidated financial
information as of December 31, 2001 has been derived from audited financial
statements; certain amounts from the three and six months ended June 30, 2001
have been reclassified for consistent presentation with current year financial
statements. It is presumed that users of this interim financial information have
read or have access to the audited financial statements for the preceding fiscal
year, which were included in the Company's Annual Report on Form 10-K. In the
opinion of management, all adjustments (consisting of normal recurring
adjustments) considered necessary for fair presentation have been included in
these interim financial statements. Operating results for the interim periods
presented are not necessarily indicative of the results that may be expected for
the full year.
The preparation of consolidated financial statements in conformity with
accounting principles generally accepted in the United States requires
management to make estimates and assumptions that affect the amounts reported in
the consolidated financial statements and accompanying notes. Actual results
could differ from such estimates and changes in such estimates may affect
amounts reported in future periods.
In December 1999, the Securities and Exchange Commission ("SEC") issued Staff
Accounting Bulletin No. 101 ("SAB 101"), "Revenue Recognition in Financial
Statements". SAB 101 specifically addresses revenue recognition issues related
to certain upfront payments or fees. In accordance with SAB 101, certain upfront
fees and payments recognized as income in prior periods are required to be
deferred and amortized into revenue over the terms of the relevant agreements or
as the on-going services are performed. For the three and six months ended June
30, 2002, the Company recognized $83,000 and $167,000 of revenue related to the
amortization of these deferred amounts, respectively. For the three and six
months ended June 30, 2001, the Company recognized $105,000 and $333,000 of
revenue related to the amortization of these deferred amounts, respectively.
In July 2001, the Financial Accounting Standards Board (the "FASB") issued
Statement of Financial Accounting Standards No. 142, "Goodwill and Other
Intangible Assets" ("SFAS No. 142"). Under SFAS No. 142, goodwill and indefinite
lived intangible assets are no longer amortized, but must be reviewed at least
annually for impairment. In the second quarter of 2002, the Company identified
reporting units and related goodwill, as defined by SFAS No. 142, and tested the
goodwill for impairment, as of December 31, 2001, using the expected present
value of future cash flows approach. As a result of this valuation process, as
well as the application of the remaining provisions of SFAS No. 142, the Company
concluded that there was no impairment of goodwill related to any of the
Company's reporting units. SFAS No. 142 also states that goodwill and intangible
assets acquired after June 30, 2001 should not be amortized. For acquisitions
completed subsequent to June 30, 2001, the Company recorded $51.0 million of
indefinite-lived intangible assets and $159.7 million of goodwill. These assets
are not subject to amortization. The statement was effective for fiscal years
beginning after December
7
15, 2001. Prior to the adoption of SFAS No. 142, the Company amortized goodwill
related to acquisitions completed prior to June 30, 2001 over estimated useful
lives ranging from 3 to 20 years. Amortization of goodwill totaled $166,000 and
$340,000 for the three and six months ended June 30, 2001. In accordance with
SFAS No. 142, the Company ceased amortization of goodwill related to such
acquisitions.
2. EARNINGS PER SHARE
The following table provides a reconciliation of the denominators for the basic
and fully diluted earnings per share computations (in thousands):
Three Months Ended Six Months Ended
June 30, June 30,
------------------- -------------------
2002 2001 2002 2001
------- ------- ------- -------
Basic earnings per share:
Weighted average number of shares 18,243 17,721 18,157 17,687
Effect of dilutive securities:
Stock options 800 456 896 249
------- ------- ------- -------
Diluted earnings per share:
Adjusted weighted average number of shares
and assumed conversions 19,043 18,177 19,053 17,936
======= ======= ======= =======
3. FINANCIAL INFORMATION BY BUSINESS SEGMENT AND GEOGRAPHIC AREA (IN THOUSANDS)
The Company operates in three business segments consisting of a product sales
business, primarily comprised of the pharmaceuticals business unit, a product
development business, primarily the aaiResearch business unit, and a
fee-for-service business, primarily the AAI International business unit. The
product sales business provides for the sales of M.V.I., Aquasol, Brethine,
Darvon, Darvocet-N and azathioprine product lines and for the commercial
manufacturing of small quantity products outsourced by other pharmaceutical
companies. In the product development segment, the Company internally develops
drugs and technologies with the objective of licensing marketing rights to third
parties in exchange for license fees and royalties. The core services provided
on a fee-for-service basis to pharmaceutical and biotechnology industries
worldwide include comprehensive formulation, testing and manufacturing
expertise, in addition to the ability to take investigational products into and
through human clinical trials. The majority of the Company's non-U.S. operations
are located in Germany.
8
Corporate income (loss) from operations includes general corporate overhead
costs and goodwill amortization, which are not directly attributable to a
business segment. Financial data by segment and geographic region are as
follows:
Three Months Ended Six Months Ended
June 30, June 30,
------------------------ ------------------------
2002 2001 2002 2001
--------- --------- --------- ---------
NET REVENUES:
Product sales $ 34,673 $ 2,143 $ 54,850 $ 4,597
Product development 6,469 4,952 8,604 8,683
--------- --------- --------- ---------
41,142 7,095 63,454 13,280
--------- --------- --------- ---------
Research revenues:
Non-clinical 14,518 15,832 31,395 33,076
Clinical 5,787 6,957 12,218 13,725
--------- --------- --------- ---------
20,305 22,789 43,613 46,801
--------- --------- --------- ---------
$ 61,447 $ 29,884 $ 107,067 $ 60,081
========= ========= ========= =========
United States $ 61,352 $ 26,581 $ 104,701 $ 53,445
Germany 3,290 4,332 6,914 8,094
Other 197 234 396 544
Less intercompany (3,392) (1,263) (4,944) (2,002)
--------- --------- --------- ---------
$ 61,447 $ 29,884 $ 107,067 $ 60,081
========= ========= ========= =========
INCOME (LOSS) FROM OPERATIONS:
Product sales $ 21,400 $ (363) $ 30,874 $ (486)
Product development 933 3,226 (1,277) 4,678
--------- --------- --------- ---------
22,333 2,863 29,597 4,192
--------- --------- --------- ---------
Research revenues:
Non-clinical (1,621) 1,197 (813) 4,204
Clinical 430 399 862 516
--------- --------- --------- ---------
(1,191) 1,596 49 4,720
--------- --------- --------- ---------
Corporate (4,814) (1,927) (8,259) (5,199)
--------- --------- --------- ---------
$ 16,328 $ 2,532 $ 21,387 $ 3,713
========= ========= ========= =========
United States $ 16,773 $ 1,996 $ 21,850 $ 2,959
Germany (288) 641 212 946
Other (157) (105) (251) (192)
--------- --------- --------- ---------
$ 16,328 $ 2,532 $ 21,387 $ 3,713
========= ========= ========= =========
9
June 30, December 31,
2002 2001
--------- ------------
TOTAL ASSETS:
Product sales $ 351,394 $ 105,541
Product development 6,692 7,832
Research revenues 52,060 55,555
Corporate 33,231 27,358
--------- ---------
$ 443,377 $ 196,286
========= =========
United States $ 422,186 $ 176,518
Germany 20,030 18,794
Other 1,161 974
--------- ---------
$ 443,377 $ 196,286
========= =========
4. TRANSACTIONS WITH RELATED PARTIES
The Company has revenue, accounts receivable and work-in-progress with Aesgen,
Inc. ("Aesgen") and Endeavor Pharmaceuticals, Inc. ("Endeavor"). Both Endeavor
and Aesgen were organized by aaiPharma Inc. and its principal shareholders and
continue to be related parties. Revenues recognized from Aesgen totaled $220,000
and $339,000 for the three and six months ended June 30, 2002. No revenues were
recognized from Aesgen for the three and six months ended June 30, 2001.
Revenues recognized from Endeavor totaled $667,000 and $966,000 for the three
and six months ended June 30, 2002, and were $108,000 and $230,000 for the three
and six months ended June 30, 2001. Services performed by the Company for Aesgen
are covered by a Subscription Agreement, whereby the Company has agreed to
receive Aesgen preferred stock in lieu of cash for the services performed. At
June 30, 2002, we had no accounts receivable or work-in-progress related to
Aesgen, and had approximately $220,000 of accounts receivable and
work-in-progress related to Endeavor.
5. DEBT
The following table presents the components of current maturities of long-term
debt and short-term debt:
June 30, December 31,
2002 2001
--------- ------------
(In thousands)
Current maturities of long-term debt and short-term debt $ 5,417 $ --
========= =========
10
The following table presents the components of long-term debt:
June 30, December 31,
2002 2001
--------- ------------
(In thousands)
U.S. bank term loan $ 92,000 $ 78,000
U.S. revolving credit facility 39,000 --
11% senior subordinated notes due 2010, net of original issue discount 173,891 --
Interest rate swap monetization deferred income 3,428 --
Fair value of interest rate swap 676 --
Obligations under asset purchase agreement 914 878
Less current maturities of long-term debt (5,417) --
--------- ---------
Total long-term debt due after one year $ 304,492 $ 78,878
========= =========
On March 28, 2002, the Company entered into a $175 million senior secured credit
facility consisting of a $75.0 million five-year revolving credit facility and a
$100 million five-year term loan facility. The term loan facility amortizes over
the full five-year term, with amortization of $5.0 million, $15.0 million, $20.0
million, $25.0 million and $35.0 million, respectively, in years one through
five. As of June 30, 2002, the Company has paid $3.3 million of the first year's
required payment plus $4.7 million of future required payments. The availability
of borrowings under the revolving credit facility is not limited by a borrowing
base. The senior credit facilities provide for variable interest rates based on
LIBOR or an alternate base rate, at the Company's option. On June 30, 2002,
30-day LIBOR was 1.84%. Such facilities are guaranteed by all domestic
subsidiaries and secured by a security interest on substantially all domestic
assets, all of the stock of domestic subsidiaries and 65% of the stock of
material foreign subsidiaries. The senior credit facilities require the payment
of certain commitment fees based on the unused portion of the revolving credit
facility. These senior credit facilities may be prepaid at any time without a
premium.
On March 28, 2002, the Company issued $175 million of senior subordinated notes
due April 1, 2010. The proceeds from the issuance of these notes were $173.9
million, which was net of the original issue discount. This discount will be
charged to interest expense over the term of the notes. These notes have a fixed
interest rate of 11% per annum and are guaranteed on a subordinated basis by all
existing domestic subsidiaries and all future domestic subsidiaries that are
owned 80% or more by the Company. The notes are not secured. Prior to the third
anniversary of the date of issuance of the notes, up to 35% of the notes are
redeemable with the proceeds of qualified sales of equity at 111% of par value.
The terms of the senior credit facilities first require repayment of all of the
indebtedness under these facilities before repurchase of any of the notes. On or
after the fourth anniversary of the date of issuance of the notes, all or any
portion of the notes are redeemable at declining premiums to par value,
beginning at 105.5%.
On March 28, 2002, the Company entered into an interest rate swap agreement to
effectively convert interest rate expense on $140 million of senior subordinated
notes for the term of the notes from an 11% fixed annual rate to a floating
annual rate equal to 6-month LIBOR plus 4.78%. On May 30, 2002, the Company sold
this swap agreement and received $4.1 million. This amount, less the interest
benefit earned through May 30, 2002, has been recorded as a premium to the
carrying amount of the notes and will be amortized into interest income over
their remaining life. Concurrent with the sale of the interest rate
11
swap, the Company entered into a new interest rate swap agreement which
effectively converted $150 million of the notes from an 11% fixed annual rate to
a floating rate equal to 6-month LIBOR plus 5.28%. On June 30, 2002, 6-month
LIBOR was 1.96%. On August 5, 2002, the Company sold this new swap agreement for
$5.6 million, which will also be recorded as a premium to the carrying amount of
the notes and amortized into interest income over their remaining life, and
entered into another interest rate swap agreement on similar terms as the May
30, 2002 agreement, at a floating rate of 6-month LIBOR plus 5.95%.
Under the terms of the senior secured credit facility and the senior
subordinated notes, the Company is required to comply with various covenants
including, but not limited to, those pertaining to maintenance of certain
financial ratios and incurring additional indebtedness. The Company was in
compliance with the covenants at June 30, 2002.
6. ACQUISITIONS
On March 28, 2002, the Company acquired the U.S. rights to the Darvon and
Darvocet-N branded product lines, which treat mild to moderate pain, and
existing inventory from Eli Lilly and Company, in a business combination
accounted for as a purchase. The Company acquired these product lines and
related intangible assets for $211.4 million. To finance this acquisition, which
included $1.8 million of inventory, the Company used the proceeds from the
senior secured credit facilities and senior subordinated notes, as described in
note 5. The Darvon and Darvocet-N product lines did not have separable assets
and liabilities associated with them, other than inventory, therefore the
Company allocated the purchase price, including acquisition related expenses, to
acquired identifiable assets, with the excess of the purchase price over the
identifiable tangible and intangible assets recorded as goodwill. Based on this
allocation, $51.2 million of intangible assets have been identified and will be
amortized over 20 years. The excess of the purchase price over identifiable
intangible assets has been classified as goodwill, which is not subject to
amortization.
12
The following unaudited pro forma consolidated financial information reflects
the results of operations for the three and six months ended June 30, 2002 and
2001, as if the above acquisition had occurred on January 1, 2001.
Three Months Ended June 30, Six Months Ended June 30,
--------------------------- -------------------------
2002 2001 2002 2001
----------- ---------- ---------- ---------
(In thousands, except per share data)
Net revenues $ 61,447 $ 47,396 $ 116,799 $ 94,558
Income before extraordinary loss 6,104 4,027 7,879 7,423
Net income 6,104 4,027 2,540 7,423
Basic earnings per share:
Income before extraordinary loss $ 0.33 $ 0.23 $ 0.43 $ 0.42
Net income $ 0.33 $ 0.23 $ 0.14 $ 0.42
Diluted earnings per share:
Income before extraordinary loss $ 0.32 $ 0.22 $ 0.41 $ 0.41
Net income $ 0.32 $ 0.22 $ 0.13 $ 0.41
These pro forma results have been prepared for comparative purposes only and do
not purport to be indicative of what operating results would have been had the
acquisitions taken place on January 1, 2001. In addition, these results are not
intended to be a projection of future results and do not reflect any synergies
that might be achieved from the combined operations.
As previously reported, the Company completed the acquisition of the M.V.I. and
Aquasol branded product lines in August 2001, and the acquisition of the
Brethine branded product line in December 2001. Revenues from the sales of these
products are included in the Company's results of operations beginning on their
acquisition dates.
7. EXTRAORDINARY LOSS
In March 2002, the Company recorded a charge of $5.3 million, net of a tax
benefit of $2.7 million, to record the write-off of deferred financing and other
costs related to its prior debt facilities and redeemable warrants.
13
8. FINANCIAL INFORMATION FOR SUBSIDIARY GUARANTORS AND NON-GUARANTORS
In the first quarter of 2002, the Company issued senior subordinated notes which
are guaranteed by certain of the Company's subsidiaries.
The following presents condensed consolidating financial information for the
Company, segregating: (1) aaiPharma Inc., which issued the notes (the "Issuer");
(2) the domestic subsidiaries, which guarantee the notes (the "Guarantor
Subsidiaries"); and (3) all other subsidiaries (the "Non-Guarantor
Subsidiaries"). The guarantor subsidiaries are wholly owned direct subsidiaries
of the Company and their guarantees are full, unconditional and joint and
several. Wholly owned subsidiaries are presented on the equity basis of
accounting. Certain reclassifications have been made to conform all of the
financial information to the financial presentation on a consolidated basis. The
principal eliminating entries eliminate investments in subsidiaries and
inter-company balances and transactions.
The following information presents consolidating statements of operations,
balance sheets and cash flows for the periods and as of the dates indicated:
Three Months Ended June 30, 2002
-------------------------------------------------------------------------------
Non-
Guarantor Guarantor
Issuer Subsidiaries Subsidiaries Eliminations Consolidated
-------------------------------------------------------------------------------
Net revenues $ 13,936 $ 47,416 $ 3,487 $ (3,392) $ 61,447
Equity earnings from subsidiaries 16,822 -- -- (16,822) --
-------- -------- -------- -------- --------
Total revenues 30,758 47,416 3,487 (20,214) 61,447
Operating costs and expenses:
Direct costs 9,726 12,871 2,647 (3,183) 22,061
Selling 1,712 3,627 420 -- 5,759
General and administrative 8,001 2,837 865 -- 11,703
Research and development 169 5,427 -- -- 5,596
-------- -------- -------- -------- --------
19,608 24,762 3,932 (3,183) 45,119
-------- -------- -------- -------- --------
Income (loss) from operations 11,150 22,654 (445) (17,031) 16,328
Other income (expense):
Interest, net 566 (7,139) 20 -- (6,553)
Net intercompany interest (584) 632 (48) -- --
Other (1,198) 1,266 1 -- 69
-------- -------- -------- -------- --------
(1,216) (5,241) (27) -- (6,484)
-------- -------- -------- -------- --------
Income (loss) before income taxes 9,934 17,413 (472) (17,031) 9,844
Provision for income taxes 3,830 -- (90) -- 3,740
-------- -------- -------- -------- --------
Net income (loss) $ 6,104 $ 17,413 $ (382) $(17,031) $ 6,104
======== ======== ======== ======== ========
14
Three Months Ended June 30, 2001
-----------------------------------------------------------------------------
Non-
Guarantor Guarantor
Issuer Subsidiaries Subsidiaries Eliminations Consolidated
-----------------------------------------------------------------------------
Net revenues $ 13,717 $ 12,864 $ 4,565 $ (1,262) $ 29,884
Equity earnings from subsidiaries 4,994 -- -- (4,994) --
-------- -------- -------- -------- --------
Total revenues 18,711 12,864 4,565 (6,256) 29,884
Operating costs and expenses:
Direct costs 8,354 5,573 2,611 (1,262) 15,276
Selling 1,935 676 280 -- 2,891
General and administrative 3,455 1,787 1,140 -- 6,382
Research and development 315 1,451 -- -- 1,766
Direct pharmaceutical start-up costs -- 1,037 -- -- 1,037
-------- -------- -------- -------- --------
14,059 10,524 4,031 (1,262) 27,352
-------- -------- -------- -------- --------
Income (loss) from operations 4,652 2,340 534 (4,994) 2,532
Other income (expense):
Interest, net (283) (3) (41) -- (327)
Net intercompany interest (2,185) 2,203 (18) -- --
Other (942) (49) 28 -- (963)
-------- -------- -------- -------- --------
(3,410) 2,151 (31) -- (1,290)
-------- -------- -------- -------- --------
Income (loss) before income taxes 1,242 4,491 503 (4,994) 1,242
Provision for income taxes 228 -- -- -- 228
-------- -------- -------- -------- --------
Net income (loss) $ 1,014 $ 4,491 $ 503 $ (4,994) $ 1,014
======== ======== ======== ======== ========
15
Six Months Ended June 30, 2002
-----------------------------------------------------------------------------
Non-
Guarantor Guarantor
Issuer Subsidiaries Subsidiaries Eliminations Consolidated
-----------------------------------------------------------------------------
Net revenues $ 30,673 $ 74,028 $ 7,310 $ (4,944) $107,067
Equity earnings from subsidiaries 18,579 -- -- (18,579) --
-------- -------- -------- -------- --------
Total revenues 49,252 74,028 7,310 (23,523) 107,067
Operating costs and expenses:
Direct costs 19,986 23,831 5,203 (4,735) 44,285
Selling 3,404 5,855 817 -- 10,076
General and administrative 14,046 5,447 1,753 -- 21,246
Research and development 416 9,657 -- -- 10,073
-------- -------- -------- -------- --------
37,852 44,790 7,773 (4,735) 85,680
-------- -------- -------- -------- --------
Income (loss) from operations 11,400 29,238 (463) (18,788) 21,387
Other income (expense):
Interest, net 453 (8,852) 23 -- (8,376)
Net intercompany interest (1,148) 1,257 (109) -- --
Other (1,091) 1,254 40 -- 203
-------- -------- -------- -------- --------
(1,786) (6,341) (46) -- (8,173)
-------- -------- -------- -------- --------
Income (loss) before income taxes and
extraordinary loss 9,614 22,897 (509) (18,788) 13,214
Provision for income taxes 5,111 -- (90) -- 5,021
-------- -------- -------- -------- --------
Income (loss) before extraordinary loss 4,503 22,897 (419) (18,788) 8,193
Extraordinary loss (1,649) (3,690) -- -- (5,339)
-------- -------- -------- -------- --------
Net income (loss) $ 2,854 $ 19,207 $ (419) $(18,788) $ 2,854
======== ======== ======== ======== ========
16
Six Months Ended June 30, 2001
-----------------------------------------------------------------------------
Non-
Guarantor Guarantor
Issuer Subsidiaries Subsidiaries Eliminations Consolidated
-----------------------------------------------------------------------------
Net revenues $ 28,775 $ 24,670 $ 8,637 $ (2,001) $ 60,081
Equity earnings from subsidiaries 7,223 -- -- (7,223) --
-------- -------- -------- -------- --------
Total revenues 35,998 24,670 8,637 (9,224) 60,081
Operating costs and expenses:
Direct costs 16,817 10,672 5,237 (2,001) 30,725
Selling 3,796 1,372 561 -- 5,729
General and administrative 8,372 3,667 2,086 -- 14,125
Research and development 1,194 2,914 -- -- 4,108
Direct pharmaceutical start-up costs -- 1,681 -- -- 1,681
-------- -------- -------- -------- --------
30,179 20,306 7,884 (2,001) 56,368
-------- -------- -------- -------- --------
Income (loss) from operations 5,819 4,364 753 (7,223) 3,713
Other income (expense):
Interest, net (499) (2) (209) -- (710)
Net intercompany interest (2,185) 2,203 (18) -- --
Other (819) (35) 167 -- (687)
-------- -------- -------- -------- --------
(3,503) 2,166 (60) -- (1,397)
-------- -------- -------- -------- --------
Income (loss) before income taxes 2,316 6,530 693 (7,223) 2,316
Provision for income taxes 486 -- -- -- 486
-------- -------- -------- -------- --------
Net income (loss) $ 1,830 $ 6,530 $ 693 $ (7,223) $ 1,830
======== ======== ======== ======== ========
17
June 30, 2002
-----------------------------------------------------------------------------
Non-
Guarantor Guarantor
Issuer Subsidiaries Subsidiaries Eliminations Consolidated
-----------------------------------------------------------------------------
ASSETS
Current assets:
Cash and cash equivalents $ 4,014 $ 133 $ 65 $ -- $ 4,212
Accounts receivable, net 11,099 26,949 2,293 -- 40,341
Work-in-progress 4,634 5,608 4,978 (3,544) 11,676
Inventories 4,066 4,956 580 (209) 9,393
Prepaid and other current assets 1,736 3,907 220 -- 5,863
--------- --------- --------- --------- ---------
Total current assets 25,549 41,553 8,136 (3,753) 71,485
Investments in and advances to subsidiaries 66,061 (46,202) -- (19,859) --
Property and equipment, net 42,366 6,102 3,957 -- 52,425
Goodwill and other intangibles, net 1,135 290,384 9,006 -- 300,525
Other assets 7,475 11,374 93 -- 18,942
--------- --------- --------- --------- ---------
Total assets $ 142,586 $ 303,211 $ 21,192 $ (23,612) $ 443,377
========= ========= ========= ========= =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current maturities of long-term debt and
short-term debt $ -- $ 5,417 $ -- $ -- $ 5,417
Accounts payable 4,282 9,626 1,693 -- 15,601
Customer advances 11,107 6,582 2,925 (3,544) 17,070
Accrued wages and benefits 1,984 1,034 1,297 -- 4,315
Interest payable 563 6,053 -- 6,616
Other accrued liabilities 1,183 3,510 114 129 4,936
--------- --------- --------- --------- ---------
Total current liabilities 19,119 32,222 6,029 (3,415) 53,955
Long-term debt, less current portion 39,000 265,492 -- -- 304,492
Other liabilities 1,343 -- -- -- 1,343
Investments in and advances to subsidiaries 59,800 (63,698) 4,027 (129) --
Redeemable warrants -- -- -- -- --
Total stockholders' equity 23,324 69,195 11,136 (20,068) 83,587
--------- --------- --------- --------- ---------
Total liabilities and stockholders' equity $ 142,586 $ 303,211 $ 21,192 $ (23,612) $ 443,377
========= ========= ========= ========= =========
18
December 31, 2001
--------------------------------------------------------------------------
Non-
Guarantor Guarantor
Issuer Subsidiaries Subsidiaries Eliminations Consolidated
--------------------------------------------------------------------------
ASSETS
Current assets:
Cash and cash equivalents $ 5,301 $ 154 $ 916 $ -- $ 6,371
Accounts receivable, net 13,189 8,415 2,690 2,300 26,594
Work-in-progress 3,871 5,099 3,794 (2,300) 10,464
Inventories 2,955 5,584 518 -- 9,057
Prepaid and other current assets 3,081 2,640 251 -- 5,972
--------- --------- --------- --------- ---------
Total current assets
28,397 21,892 8,169 -- 58,458
Investments in and advances to subsidiaries
66,061 (46,202) -- (19,859) --
Property and equipment, net 27,724 5,841 3,470 -- 37,035
Goodwill and other intangibles, net 1,071 79,383 8,050 -- 88,504
Other assets 7,372 4,836 81 -- 12,289
--------- --------- --------- --------- ---------
Total assets $ 130,625 $ 65,750 $ 19,770 $ (19,859) $ 196,286
========= ========= ========= ========= =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current maturities of long-term debt and
short-term debt $ -- $ 14 $ -- $ (14) $ --
Accounts payable 3,626 10,236 1,582 -- 15,444
Customer advances 3,883 6,874 2,592 -- 13,349
Accrued wages and benefits 2,040 958 881 -- 3,879
Other accrued liabilities 2,821 2,572 302 (402) 5,293
--------- --------- --------- --------- ---------
Total current liabilities 12,370 20,654 5,357 (416) 37,965
Long-term debt, less current portion -- 78,878 -- -- 78,878
Other liabilities 224 -- -- -- 224
Investments in and advances to subsidiaries 79,157 (83,625) 4,052 416 --
Redeemable warrants 2,855 -- -- -- 2,855
Stockholders' equity 36,019 49,843 10,361 (19,859) 76,364
--------- --------- --------- --------- ---------
Total liabilities and stockholders' equity $ 130,625 $ 65,750 $ 19,770 $ (19,859) $ 196,286
========= ========= ========= ========= =========
19
Six Months Ended June 30, 2002
--------------------------------------------------------------------
Non-
Guarantor Guarantor
Issuer Subsidiaries Subsidiaries Eliminations Consolidated
--------------------------------------------------------------------
Cash flows from operating activities:
Income (loss) before extraordinary loss $ 4,503 $ 22,897 $(419) $ (18,788) $ 8,193
Adjustments to reconcile net income (loss)
before extraordinary
loss to net cash provided by (used in)
operating activities:
Depreciation and amortization 2,307 1,661 504 -- 4,472
Other 3 12 102 -- 117
Changes in operating assets and liabilities:
Trade and other receivables 2,090 (18,533) 716 2,300 (13,427)
Work-in-progress (764) (508) (733) 1,244 (761)
Inventories (1,111) 627 -- 209 (275)
Prepaid and other assets 1,242 (14,271) 59 -- (12,970)
Accounts payable 655 (610) (77) -- (32)
Customer advances 7,225 (292) 24 (3,544) 3,413
Interest payable 563 5,682 -- -- 6,245
Accrued wages and benefits and other accrued
liabilities (3,429) 3,188 (394) 531 (104)
Intercompany receivables and payables (39,586) 21,576 (24) 18,034 --
--------- --------- ----- --------- ---------
Net cash (used in) provided by operating activities (26,302) 21,429 (242) (14) (5,129)
--------- --------- ----- --------- ---------
Cash flows from investing activities:
Purchases of property and equipment (16,865) (937) (745) -- (18,547)
Acquisitions -- (211,997) -- -- (211,997)
Other (151) -- -- -- (151)
--------- --------- ----- --------- ---------
Net cash (used in) investing activities (17,016) (212,934) (745) -- (230,695)
--------- --------- ----- --------- ---------
Cash flows from financing activities:
Proceeds from long-term borrowings 49,400 199,355 -- -- 248,755
Payments on long-term borrowings (10,400) (8,014) -- 14 (18,400)
Issuance of common stock 3,031 -- -- -- 3,031
Other -- 143 27 -- 170
--------- --------- ----- --------- ---------
Net cash provided by financing activities 42,031 191,484 27 14 233,556
--------- --------- ----- --------- ---------
Net increase (decrease) in cash and cash equivalents (1,287) (21) (960) -- (2,268)
Effect of exchange rate changes on cash -- -- 109 -- 109
Cash and cash equivalents, beginning of year 5,301 154 916 -- 6,371
--------- --------- ----- --------- ---------
Cash and cash equivalents, end of period $ 4,014 $ 133 $ 65 $ -- $ 4,212
========= ========= ===== ========= =========
20
Six Months Ended June 30, 2001
----------------------------------------------------------------------
Non-
Guarantor Guarantor
Issuer Subsidiaries Subsidiaries Eliminations Consolidated
----------------------------------------------------------------------
Cash flows from operating activities:
Net income (loss) $ 1,830 $ 6,530 $ 693 $ (7,223) $ 1,830
Adjustments to reconcile net income (loss) to net cash
provided by (used in) operating activities:
Depreciation and amortization 2,438 507 643 -- 3,588
Other 453 358 58 -- 869
Changes in operating assets and liabilities:
Trade and other receivables (1,818) (3,114) 174 -- (4,758)
Work-in-progress 1,475 (965) (1,908) -- (1,398)
Inventories 702 (21) 119 -- 800
Prepaid and other assets 173 339 (126) -- 386
Accounts payable (769) (359) 12 -- (1,116)
Customer advances 33 (494) 746 -- 285
Interest payable (64) -- -- -- (64)
Accrued wages and benefits and other accrued
liabilities (541) 118 702 -- 279
Intercompany receivables and payables (6,015) (3,056) 1,848 7,223 --
-------- -------- -------- -------- --------
Net cash (used in) provided by operating activities (2,103) (157) 2,961 -- 701
-------- -------- -------- -------- --------
Cash flows from investing activities:
Purchases of property and equipment (1,471) (352) (738) -- (2,561)
Proceeds from sales of property and equipment 2,757 293 -- -- 3,050
Other (104) -- -- -- (104)
-------- -------- -------- -------- --------
Net cash provided by (used in) investing activities 1,182 (59) (738) -- 385
-------- -------- -------- -------- --------
Cash flows from financing activities:
Net payments on short-term debt 450 -- (1,552) -- (1,102)
Payments on long-term borrowings (304) (32) -- -- (336)
Issuance of common stock 1,115 -- -- -- 1,115
Other 41 7 (35) -- 13
-------- -------- -------- -------- --------
Net cash (used in) provided by financing activities 1,302 (25) (1,587) -- (310)
-------- -------- -------- -------- --------
Net increase in cash and cash equivalents 381 (241) 636 -- 776
Effect of exchange rate changes on cash -- -- (8) -- (8)
Cash and cash equivalents, beginning of year 639 497 89 -- 1,225
-------- -------- -------- -------- --------
Cash and cash equivalents, end of period $ 1,020 $ 256 $ 717 $ -- $ 1,993
======== ======== ======== ======== ========
21
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
Our quarterly results have been, and we expect them to continue to be, subject
to fluctuations. Quarterly results can fluctuate as a result of a number of
factors, including without limitation, the commencement, completion or
cancellation of large contracts, demand for our pharmaceutical product lines,
ability of contract manufacturers to supply conforming products on a timely
basis, costs and results of ongoing and future litigation by and against us,
progress of ongoing contracts, amounts recognized for licensing and royalty
revenues, timing and amounts of start-up expenses for new facilities, timing and
level of research and development expenditures, and changes in the mix of
services. Because a large percentage of our operating costs are relatively
fixed, variations in the timing and progress of large contracts, changes in the
demand for our services and products, or the recognition of licensing and
royalty revenues (on projects for which associated expense may have been
recognized in prior periods) can materially affect our quarterly results.
Accordingly, we believe that comparisons of our quarterly financial results may
not be meaningful.
RESULTS OF OPERATIONS:
The following table presents the net revenues for each of our business units and
our consolidated expenses and net income and each item expressed as a percentage
of consolidated net revenues:
Three Months Ended June 30, Six Months Ended June 30,
------------------------------------------- ------------------------------------------
2002 2001 2002 2001
------------------- ------------------- -------------------- -----------------
(dollars in thousands)
Net revenues:
Product sales $ 34,673 56% $ 2,143 7% $ 54,850 52% $ 4,597 8%
Product development 6,469 11% 4,952 17% 8,604 8% 8,683 14%
-------- ------ -------- ------ --------- ------ -------- ----
41,142 67% 7,095 24% 63,454 60% 13,280 22%
-------- ------ -------- ------ --------- ------ -------- ----
Research revenues:
Non-clinical 14,518 24% 15,832 53% 31,395 29% 33,076 55%
Clinical 5,787 9% 6,957 23% 12,218 11% 13,725 23%
-------- ------ -------- ------ --------- ------ -------- ----
20,305 33% 22,789 76% 43,613 40% 46,801 78%
-------- ------ -------- ------ --------- ------ -------- ----
$ 61,447 100% $ 29,884 100% $ 107,067 100% $ 60,081 100%
======== ====== ======== ====== ========= ====== ======== ====
Direct costs $ 22,061 36% $ 15,276 51% $ 44,285 41% $ 30,725 51%
Selling 5,759 9% 2,891 10% 10,076 9% 5,729 10%
General and administrative 11,703 19% 6,382 21% 21,246 20% 14,125 24%
Research and development 5,596 9% 1,766 6% 10,073 9% 4,108 7%
Direct pharmaceutical start-up costs -- -- 1,037 3% -- -- 1,681 3%
Income from operations 16,328 27% 2,532 8% 21,387 20% 3,713 6%
Interest expense, net (6,553) (11%) (327) (1%) (8,376) (8%) (710) (1%)
Provision for income taxes 3,740 6% 228 1% 5,021 5% 486 1%
Net income 6,104 10% 1,014 3% 2,854 3% 1,830 3%
22
SECOND QUARTER 2002 COMPARED TO SECOND QUARTER 2001
Our consolidated net revenues for the quarter ended June 30, 2002 increased 106%
to $61.4 million, from $29.9 million in the second quarter of 2001. Net revenues
from product sales increased to $34.7 million in 2002, from $2.1 million in
2001, due to sales of our M.V.I., Aquasol and Brethine products, which we
acquired in the second half of 2001 and sales of Darvon and Darvocet-N, which we
acquired at the end of the first quarter of 2002. Because these acquired product
lines will contribute revenues for the full year ending December 31, 2002, we
have planned for significantly increased net revenues and expense from these
product lines for 2002. Net revenues from commercial manufacturing of products
marketed by other pharmaceutical companies, which is included in product sales,
contributed $0.8 million and $2.1 million to net revenues from product sales in
the second quarters of 2002 and 2001, respectively.
Net revenues from product development increased 31% in the second quarter of
2002 to $6.5 million, from $5.0 million in 2001, primarily due to an increase in
product development revenues under our significant development agreement, from
$4.1 million in the second quarter of 2001 to $5.7 million in the second quarter
of 2002. This development agreement is described in the "Management's Discussion
and Analysis of Financial Condition and Results of Operations" section of our
Form 10-K for the fiscal year ended December 31, 2001. We expect product
development revenues to be slightly lower on a quarterly basis over the
remainder of the year.
Net revenues from our research revenues business decreased 11% in the second
quarter of 2002 to $20.3 million, from $22.8 million in 2001. Non-clinical
research revenues decreased by 8% in 2002 to $14.5 million, a decrease of $1.3
million over the prior year, due primarily to a lower level of bioanalytical
revenues in our U.S. operations and Phase I pre-clinical revenues in Europe.
Clinical research revenues decreased by 17% in 2002 to $5.8 million, from $7.0
million in 2001. This decrease was primarily attributable to the re-deployment
of a portion of our internal resources and capabilities from external
revenue-producing projects to internal research and development projects.
Gross margin dollars, or net revenues less direct costs, increased $24.8
million, or 170%, to $39.4 million, from $14.6 million in the second quarter of
2001, reflecting the benefit from our increased product sales revenues in 2002
over the prior year. As a percentage of net revenues, gross margin dollars
increased to 64% in the second quarter of 2002 from 49% in the second quarter of
2001. The higher margins generated by our product sales business were partially
offset by decreases in revenues and gross margin percentage from our research
revenues business.
Selling expenses increased 99% in the second quarter of 2002 to $5.8 million,
from $2.9 million in 2001. This increase is primarily due to additional selling
expenses incurred by our product sales business associated with marketing and
promoting our new products, maintaining and enhancing distribution channels, and
developing our product sales force. As a percentage of net revenues, selling
expenses in the second quarter of 2002 decreased slightly from the second
quarter of 2001.
General and administrative costs increased 83% in the second quarter of 2002 to
$11.7 million, from $6.4 million in 2001. This increase was primarily due to
expenses related to the management build-up for our product sales business. As a
percentage of net revenues, general and administrative expenses in the second
quarter of 2002 decreased to 19%, from 21% in the second quarter of 2001, a
trend that we expect to continue throughout the year.
23
Research and development expenses were approximately 9% of net revenues, or $5.6
million, in the second quarter of 2002, an increase from 6% of net revenues, or
$1.8 million, in 2001. This increase resulted primarily from clinical trials we
started in the first quarter of 2002 for our ProSorb-D pain management product.
In general, we target annual research and development expenses to be
approximately 8% to 10% of our estimated net revenues.
There were no direct pharmaceutical start-up costs recorded in the second
quarter of 2002, as compared to $1.0 million in the second quarter of 2001.
These costs were incurred prior to our acquisition of any pharmaceutical product
lines in 2001 and were expensed as incurred.
Net interest expense increased to $6.6 million in the second quarter of 2002,
from $0.3 million in 2001. This $6.3 million increase is primarily attributable
to the borrowings that funded our product line acquisitions in the second half
of 2001 and the first quarter of 2002. We have planned for significantly higher
net interest expense in 2002, arising from the debt incurred to fund these
acquisitions.
Consolidated income from operations was $16.3 million in the second quarter of
2002, or $13.8 million higher than the prior year. This increase is primarily
due to the expansion of our product sales business. This increase was partially
offset by decreases in our research revenues business and our increased R&D
spending.
Income from operations for our product sales business was $21.4 million in the
second quarter of 2002, compared to a loss from operations of ($0.4) million in
the prior year. This increase is attributable to the revenues from our M.V.I.,
Aquasol, Brethine, Darvon and Darvocet-N product lines, which we acquired in the
second half of 2001 and first quarter of 2002.
Income from operations for our product development business was $0.9 million in
the second quarter of 2002, compared to income from operations of $3.2 million
in 2001. This change resulted from our increased research and development
spending, as discussed above.
We recorded a loss from operations for our research revenues business of ($1.2)
million in the second quarter of 2002, compared to income from operations of
$1.6 million in 2001. This decrease is primarily due to the decline in
fee-for-service revenues, as described above.
Unallocated corporate expenses increased in the second quarter of 2002 to $4.8
million, from $1.9 million in 2001. This higher level was due to additions to
our corporate infrastructure to accommodate the expansion of our overall
business, increased legal fees to support our intellectual property and lower
reserve needs on customer balances reflected in the prior year results. As a
percentage of net revenues, unallocated corporate expenses in the second quarter
of 2002 increased to 8%, from 6% in the second quarter of 2001.
We recorded a tax provision of $3.7 million in the second quarter of 2002, based
on an effective tax rate of 38%. This rate is approximately equal to the
statutory rate. Our effective tax rate for the second quarter of 2001 was 24%,
which reflected the utilization of tax loss-carryforwards generated by our
European operations.
24
SIX MONTHS ENDED JUNE 30, 2002 COMPARED TO SIX MONTHS ENDED JUNE 30, 2001
Our consolidated net revenues for the six months ended June 30, 2002 increased
78% to $107.1 million, from $60.1 million in the first half of 2001. Net
revenues from product sales increased to $54.9 million in 2002, from $4.6
million in 2001, due to sales of our M.V.I., Aquasol and Brethine products,
which we acquired in the second half of 2001 and sales of Darvon and Darvocet-N,
which we acquired at the end of the first quarter in 2002. Net revenues from
commercial manufacturing of products marketed by other pharmaceutical companies,
which is included in product sales, contributed $3.8 million and $4.6 million to
net revenues from product sales in the first six months of 2002 and 2001,
respectively.
Net revenues from product development decreased 1% in the first half of 2002 to
$8.6 million, from $8.7 million in the first half of 2001. Product development
revenues under our significant development agreement increased from $6.7 million
in the first half of 2001 to $7.1 million in the first half of 2002.
Net revenues from our research revenues business decreased 7% in the first half
of 2002 to $43.6 million, from $46.8 million in the first half of 2001.
Non-clinical research revenues decreased by 5% in 2002 to $31.4 million, a
decrease of $1.7 million over the prior year, due primarily to a lower level of
bioanalytical revenues in our U.S. operations and Phase I pre-clinical revenues
in Europe. Clinical research revenues decreased by 11% in 2002 to $12.2 million,
from $13.7 million in 2001. This decrease was primarily attributable to the
re-deployment of a portion of our internal resources and capabilities from
external revenue-producing projects to internal research and development
projects.
Gross margin dollars increased $33.4 million to $62.8 million, from $29.4
million in the first half of 2001, reflecting the benefit from our increased
product sales revenues. As a percentage of net revenues, gross margin dollars
increased to 59% in the first half of 2002 from 49% in the first half of 2001.
The higher margins generated by our product sales business were partially offset
by decreases in revenues and gross margin percentage from our research revenues
business.
Selling expenses increased 76% in the first half of 2002 to $10.1 million, from
$5.7 million in 2001. This increase is principally due to additional selling
expenses incurred by our product sales business associated with marketing and
promoting our new products, maintaining and enhancing distribution channels, and
developing our product sales force. As a percentage of net revenues, selling
expenses in the first half of 2002 remained consistent with the first half of
2001.
General and administrative costs increased 50% in the first half of 2002 to
$21.2 million, from $14.1 million in 2001. This increase was primarily due to
expenses related to the management build-up for our product sales business. As a
percentage of net revenues, general and administrative expenses in the first
half of 2002 decreased to 20%, from 24% in the first half of 2001, a trend that
we expect to continue throughout the year.
Research and development expenses were approximately 9% of net revenues, or
$10.1 million, in the first half of 2002, an increase from 7% of net revenues,
or $4.1 million, in 2001. As previously discussed, this increase resulted
primarily from clinical trials started in the first quarter of 2002 for our
ProSorb-D pain management product.
25
There were no direct pharmaceutical start-up costs recorded in the first half of
2002, as compared to $1.7 million in the first half of 2001. These costs were
incurred prior to our acquisition of any pharmaceutical product lines in 2001
and were expensed as incurred.
Net interest expense increased to $8.4 million in the first half of 2002, from
$0.7 million in 2001. This increase is primarily attributable to the borrowings
that funded our product line acquisitions.
Consolidated income from operations was $21.4 million in the first half 2002, or
$17.7 million higher than the prior year, and is due to the expansion of our
product sales business.
Income from operations for our product sales business was $30.9 million in the
first half of 2002, compared to a loss from operations of ($0.5) million in the
prior year. This increase is attributable to the revenues from our product line
acquisitions.
The loss from operations for our product development business was ($1.3) million
in the first half of 2002, compared to income from operations of $4.7 million in
2001. This change resulted from the increased research and development spending
in the first half of 2002, as discussed above.
We recorded income from operations for our research revenues business of $0.1
million in the first half of 2002, compared to $4.7 million in 2001. This
decrease is primarily due to the decline in research revenues, as described
above.
Unallocated corporate expenses increased in the first half of 2002 to $8.3
million, from $5.2 million in 2001. This increase was due to additions to our
corporate infrastructure to accommodate our expansion and increased legal fees
to support our intellectual property. As a percentage of net revenues,
unallocated corporate expenses in the first half of 2002 decreased to 8%, from
9% in the first half of 2001.
We recorded a tax provision of $5.0 million in the first half of 2002, based on
an effective tax rate of 38%. This rate is approximately equal to the statutory
rate. Our effective tax rate for the first half of 2001 was 21%, which reflected
the utilization of tax loss-carryforwards generated by our European operations.
In March 2002, we recorded an extraordinary loss of $5.3 million, net of a tax
benefit of $2.7 million, to record the write-off of deferred financing and other
costs related to our prior debt facilities and redeemable warrants.
LIQUIDITY AND CAPITAL RESOURCES
Historically, we have funded our businesses with cash flows provided by
operations and proceeds from borrowings. Cash flow used in operations in the
first six months of 2002 was $5.1 million, compared to cash provided by
operating activities of $0.7 million in the first six months of 2001. This
change was primarily due to an increase in accounts receivable related to the
product lines we acquired and prepaid financing fees related to the financing of
our acquisitions, partially offset by the increase in income and interest
payable on our senior subordinated notes. In the second quarter of 2002, we
generated cash from operating activities of $14.5 million, which was provided by
our net income and increases in interest payable and customer advances,
partially offset by an increase in accounts receivable related to our product
sales.
26
Cash used in investing activities was $230.7 million in the first half of 2002
compared to cash provided by investing activities of $0.4 million in the first
half of 2001. This included $212.0 million related to our acquisition of the
Darvon and Darvocet-N branded product lines as further described below, and
$14.1 million for the purchase of assets formerly covered by our tax retention
operating lease, including our corporate headquarters in Wilmington, N.C. and a
laboratory and clinical facility in Chapel Hill, N.C.
Cash provided by financing activities during the first half of 2002 was $233.6
million, primarily representing net proceeds of $248.8 million in additional
borrowings under our new debt facilities, as described below, and $3.0 million
of cash proceeds from the exercise of stock options, partially offset by the
repayment of $18.4 million of these borrowings in the second quarter.
In March 2001, we completed a sale/leaseback transaction on manufacturing
equipment, which provided cash of $3.1 million. The lease has a five-year term
and requires payments of approximately $0.6 million annually.
On March 28, 2002, we acquired the U.S. rights to the Darvon and Darvocet-N
branded product lines and existing inventory from Eli Lilly and Company for
$211.4 million in cash, subject to potential reduction based on the net sales of
these products after the closing of the acquisition. In connection with the
acquisition, we entered into $175 million of senior credit facilities, issued
$175 million of senior subordinated notes due 2010, repaid all $78 million of
borrowings outstanding under our prior senior credit facilities, and terminated
our tax retention operating lease and purchased the underlying properties.
Our $175 million senior secured credit facilities consist of a $75 million
five-year revolving credit facility and a $100 million five-year term loan
facility. The term loan facility amortizes over the full five-year term, with
amortization of $5 million, $15 million, $20 million, $25 million and $35
million, respectively, in years one through five. The availability of borrowings
under our revolving credit facility is not limited by a borrowing base. Our
senior credit facilities provide for variable interest rates based on LIBOR or
an alternate base rate, at our option. Such facilities are guaranteed by all of
our domestic subsidiaries and secured by a security interest on substantially
all of our domestic assets, all of the stock of our domestic subsidiaries, and
65% of the stock of our material foreign subsidiaries. Our senior credit
facilities require the payment of certain commitment fees based on the unused
portion of the revolving credit facility. Under the terms of the credit
agreement for our senior credit facilities, we are required to comply with
various covenants including, but not limited to, those pertaining to maintenance
of certain financial ratios and incurrence of additional indebtedness. These
senior credit facilities may be prepaid at our option at any time without a
premium.
On March 28, 2002, we issued $175 million of senior subordinated unsecured notes
due 2010. These notes have a fixed interest rate of 11% per annum and are
guaranteed on a subordinated basis by all of our existing domestic subsidiaries
and all of our future domestic subsidiaries of which we own 80% or more of the
equity interests. Prior to March 28, 2005, up to 35% of the notes are redeemable
with the proceeds of qualified sales of equity at 111% of par value. The terms
of our senior credit facilities require us to first repay all of the
indebtedness under these facilities before we could repurchase any of the notes.
On or after March 28, 2006, all or any portion of the notes are redeemable at
declining premiums to par value, beginning at 105.5%. Under the terms of the
indenture for the notes, we are
27
required to comply with various covenants including, but not limited to, a
covenant relating to incurrence of additional indebtedness.
On March 28, 2002, we entered into an interest rate swap agreement to
effectively convert interest rate expense on $140 million of our senior
subordinated notes for the term of the notes from an 11% fixed annual rate to a
floating annual rate equal to 6-month LIBOR plus 4.78%. On May 30, 2002, we sold
this swap agreement and received $4.1 million. This amount, less the interest
benefit earned through May 30, 2002, has been recorded as a premium to the
carrying amount of the notes and will be amortized into interest income over
their remaining life. Concurrent with the sale of the interest rate swap, we
entered into a new interest rate swap agreement, which effectively converted
$150 million of the notes from an 11% fixed annual rate to a floating rate equal
to 6-month LIBOR plus 5.28%. On June 30, 2002, 6-month LIBOR was 1.96%. On
August 5, 2002, we sold this new swap agreement for $5.6 million, which will
also be recorded as a premium to the carrying amount of the notes and amortized
into interest income over their remaining life, and entered into another
interest rate swap agreement on similar terms as the May 30, 2002 agreement at a
floating rate of 6-month LIBOR plus 5.95%.
Our liquidity needs increased significantly during the first half of 2002. After
giving effect to our completed branded product line acquisitions, our annual net
interest expense may exceed $25 million in 2002. We will make $2 million in
payments in the next two years, including $1 million in August 2002, and may
have to make contingent payments in the next several years of $47 million in
connection with our product line acquisitions of M.V.I. and Aquasol, of which
$43.5 million is potentially due in August 2004. In addition, we may have to
make contingent payments of $5 million over five years in connection with the
purchase of our Charleston, South Carolina manufacturing facility. We have $5.4
million of principal repayments due in the next twelve months under our senior
credit facilities and will make an interest payment on the senior subordinated
notes of $9.6 million in October 2002. This interest payment will be reduced by
approximately $1.0 million to be received under our interest rate swap
agreement.
On April 5, 2002, we filed a Registration Statement on Form S-1, proposing to
sell 1.5 million shares of our common stock to the public. An additional 1.1
million shares were proposed to be sold by other selling stockholders. On May
24, 2002, we withdrew the Registration Statement because the terms obtainable in
the market place were not sufficiently attractive to warrant proceeding with the
sale of the shares.
We believe that our senior credit facilities and cash flow provided by
operations will be sufficient to fund near-term growth and fund our guaranteed
and contingent payment obligations arising from our acquisitions. We may require
additional financing to pursue other acquisition opportunities or for other
reasons. We may from time to time seek to obtain additional funds through the
public or private issuance of equity or debt securities. While we remain
confident that we can obtain additional financing, if necessary, we cannot
assure you that additional financing will be available or that the terms will be
acceptable to us.
FORWARD LOOKING STATEMENTS, RISK FACTORS AND "SAFE HARBOR" LANGUAGE
This report contains certain forward-looking statements, within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended.
28
All statements that include the words "may," "will," "estimate," "intend,"
"project," "target," "objective," "goal," "should," "could," "might,"
"continue," "believe," "expect," "plan," "anticipate" and other similar words
are intended to be forward-looking statements. We assume no obligation to update
forward-looking statements, or any other statements, contained in this report.
For purposes of illustration, these forward-looking statements include
statements relating to the amount, timing, and use of proceeds of future
issuance of equity; the sufficiency of our senior credit facilities and cash
flow from operations to fund near-term growth and to fund guaranteed and
contingent acquisition payment obligations; the availability of future
financing, if necessary; the expected amounts owed under future contingent
acquisition payment obligations; anticipated product development and research
services net revenues and profitability levels and trends; expected levels of
future net interest expenses; targeted research and development expenditures as
a percentage of net revenues; anticipated levels of sales and general and
administrative costs as a percentage of net revenues; and expected net revenues,
expenses and profitability of our product sales.
Although we believe that the expectations underlying any of our forward-looking
statements are reasonable, these expectations may prove to be incorrect and all
of these statements are subject to risks and uncertainties. Should one or more
of these risks and uncertainties materialize, or should underlying assumptions,
projections or expectations prove incorrect, actual results, performance or
financial condition may vary materially and adversely from those anticipated,
estimated or expected. We have identified below some important factors that
could cause our forward-looking statements to differ materially from actual
results, performance or financial condition:
- We have recently transitioned our company to a specialty
pharmaceutical company with challenges and risks that we have
not historically faced in our fee-for-services and product
development businesses;
- We may devote significant operational and financial resources
to develop products that we may never be able to successfully
commercialize;
- We have increased our sales and net income through a series of
acquisitions of branded products, and we intend to seek more
acquisition opportunities; we may have overpaid, or may
overpay in the future, for a branded product line that may not
produce sufficient cash flow to repay our debt, including
indebtedness incurred in connection with that acquisition;
- We are dependent on third parties for essential business
functions and problems with these third-party arrangements
could materially adversely affect our ability to manufacture
and sell products and our financial condition and results of
operations;
- Competition from the sale of generic products and the
development by other companies of new branded products could
cause the revenues from our branded products to decrease
significantly;
- We may be unable to obtain government approval for our
products or comply with government regulations relating to our
business; and
- Changes in government regulations may favor sales of generic
products that compete with our branded products.
Additional factors that may cause the actual results to differ materially are
discussed in Exhibit 99.1 to this report hereto and incorporated herein by
reference and in our recent filings with the SEC, including, but not limited to,
our registration statements, as amended, our Annual Report on Form 10-K filed
with the
29
SEC on March 11, 2002, including the exhibits attached or incorporated therein,
our Form 10-Q filed with the SEC on May 15, 2002, including the exhibits
thereof, our Form 8-K reports, and other periodic filings. Whenever you read or
hear any subsequent written or oral forward-looking statements attributable to
us or any person acting on our behalf, you should keep in mind the cautionary
statements contained or referred to in this section. We do not undertake any
obligation to release publicly any revisions to these forward-looking statements
to reflect events or circumstances after the date of this document or to reflect
the occurrence of unanticipated events.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a result of global operating activities, we are exposed to risks associated
with changes in foreign exchange rates, principally exchange rates between the
U.S. dollar and the euro. As foreign exchange rates change, the U. S. dollar
equivalent of revenues and expenses denominated in foreign currencies change. If
the exchange rate between the euro and the U.S. dollar were to change by 10%,
year to date net income for June 30, 2002 would have changed by $35,000 due to
the change in reported results from European operations.
We are also exposed to fluctuations in interest rates on borrowings under our
senior credit facilities and on $150 million of our senior subordinated notes,
due to our entering into the interest rate swap agreement discussed above. The
interest rates payable on these borrowings are based on LIBOR. If LIBOR rates
were to increase by 1%, annual interest expense on variable rate debt would
increase by approximately $3.2 million, or $800,000 per quarter.
30
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We are party to lawsuits and administrative proceedings incidental to the normal
course of our business. We do not believe that any liabilities related to such
lawsuits or proceedings will have a material adverse effect on our financial
condition, results of operations or cash flows. While we cannot predict the
outcomes of these suits, we intend to vigorously pursue all defenses available.
In cases where we have initiated an action, we intend to prosecute our claims to
the full extent of our rights under the law.
We are a party to a number of legal actions with generic drug companies. We
filed three cases in the United States District Court for the Eastern District
of North Carolina claiming infringement of certain of our fluoxetine
hydrochloride patents. Fluoxetine hydrochoride is an active ingredient in the
drug marketed by Eli Lilly as Prozac. Each of the defendants in these three
actions, Dr. Reddy's Laboratories Ltd., a pharmaceutical company based in India,
and its U.S. affiliate, Dr. Reddy's Laboratories, Inc. (formerly Reddy-Cheminor,
Inc.), Barr Laboratories, Inc., and PAR Pharmaceuticals, Inc. sells a generic
fluoxetine hydrochloride product in the United States.
In the first action, filed in August 2001, we alleged that the defendants are
infringing our fluoxetine hydrochloride Form A patent (U.S. Patent No.
6,258,853) and are seeking an injunction to prevent the sale of products that
infringe this patent, as well as compensatory and punitive damages and
attorney's fees. In the second case, filed in October 2001, we alleged that the
defendants are infringing three additional fluoxetine patents (U.S. Patent Nos.
6,310,250, 6,310,251 and 6,313,350) and are seeking an injunction to prevent the
defendants from selling infringing fluoxetine products, and monetary damages. In
the third action, filed in November 2001, we have brought similar claims against
the defendants regarding a fifth fluoxetine patent (U.S. Patent No. 6,316,672).
In each case, the defendants have filed counterclaims alleging patent
invalidity, violations of the North Carolina Unfair Trade Practices Act and
tortious interference with the defendants' distribution agreements. We have
denied the substantive allegations of their claims. These cases are all in the
initial stages and discovery is just beginning. It is possible that the patents
subject to these lawsuits will be found invalid or unenforceable.
We are also involved in three actions centered on our omeprazole-related
patents. Omeprazole is the active ingredient found in Prilosec, a drug sold by
AstraZeneca. Two cases have been filed against us by Dr. Reddy's Laboratories
Ltd. and Dr. Reddy's Laboratories, Inc. in the United States District Court for
the Southern District of New York in July 2001 and November 2001. These
plaintiffs have sought but, as of March 1, 2002 have not obtained, approval from
the FDA to market a generic form of Prilosec. The plaintiffs in these cases are
challenging the validity of five patents that we have obtained relating to
omeprazole (U.S. Patent Nos. 6,262,085, 6,262,086, 6,268,385, 6,312,712 and
6,312,723) and are seeking a declaratory judgment that their generic form of
Prilosec does not infringe these patents. Additionally, they have alleged
misappropriation of trade secrets, tortious interference, unfair competition and
violations of the North Carolina Unfair Trade Practice Act. We have denied the
substantive allegations made in these cases. Both cases are in the initial
stages and discovery is just beginning.
The third case involving our omeprazole patents was brought in August 2001 by
Andrx Pharmaceuticals, Inc. in the United States District Court for the Southern
District of New York. Andrx has received FDA approval for its generic omeprazole
product. However, to our knowledge, it is not currently marketing this
31
drug in the U.S. Andrx is challenging the validity of three of our omeprazole
patents (U.S. Patent Nos. 6,262,085, 6,262,086, and 6,268,385), and is also
seeking a declaratory judgment that its generic omeprazole product does not
infringe these patents. Furthermore, Andrx claims violations of federal and
state antitrust laws with respect to the licensing of these omeprazole patents
and is seeking injunctive relief and unspecified treble damages. We have denied
the substantive allegations made by Andrx. This case is in the initial stages of
discovery. It is possible that the patents subject to these lawsuits will be
found invalid or unenforceable.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
On May 17, 2002, the Company held its annual meeting of stockholders. The total
number of shares outstanding as of the record date, March 25, 2002, was
18,162,076. The matters voted on at the meeting and the results are as follows:
Election of Directors:
John M. Ryan Joseph H. Gleberman Richard G. Morrision, Ph.D.
------------ ------------------- ---------------------------
Votes For 17,264,411 17,239,766 17,264,526
Votes Withheld 223,227 247,872 223,112
Amend the 1997 Stock Option Plan authorizing the issuance of an additional
1,250,000 options:
Votes For 10,335,405
Votes Against 4,611,614
Abstentions 409,094
Amend the 2000 Stock Option Plan for Non-employee Directors authorizing the
issuance of an additional 250,000 options:
Votes For 10,375,754
Votes Against 4,572,610
Abstentions 407,749
Amend the Company's Certificate of Incorporation increasing the size of the
Board of Directors to ten members:
Votes For 17,301,776
Votes Against 28,982
Abstentions 156,880
Ratify the appointment of Ernst & Young as independent auditors of the Company
for the fiscal year ending December 21, 2002:
Votes For 16,395,364
Votes Against 1,089,919
Abstentions 2,355
No other matters were voted on at the meeting.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
EXHIBITS:
A list of the exhibits required to be filed as part of this Report on Form 10-Q
is set forth in the "Exhibit Index", which immediately precedes such exhibits,
and is incorporated herein by reference.
32
REPORTS ON FORM 8-K:
During the second quarter of 2002, the Company filed the following Current
Reports on Form 8-K:
- Dated April 2, 2002, reporting the completion of the
acquisition of the Darvon and Darvocet-N branded product lines
from Eli Lilly and Company.
- Dated April 12, 2002, to file an amendment to the March 7,
2002 Form 8-K, which announced the agreement to acquire the
Darvon and Darvocet-N branded product lines.
- Dated May 3, 2002, to file a press release reporting the
Company's results of operations for the three months ended
March 31, 2002 and announce the appointment of Dr. Phillip
Tabbiner as the Company's Chief Executive Officer and Dr.
Frederick Sancilio as Executive Chairman of the Board of
Directors.
- Dated May 23, 2002, to file an amendment to the January 24,
2002 Form 8-K to provide additional information regarding the
acquisitions of the M.V.I. and Aquasol branded product lines.
- Dated May 24, 2002, to file an amendment to the March 11, 2002
Form 8-K to provide audited special purpose financial
statements related to the acquisition of the Darvon and
Darvocet-N branded product lines.
- Dated June 14, 2002, to file an amendment to the March 7, 2002
Form 8-K to provide additional information regarding the
acquisition of the Darvon and Darvocet-N branded product
lines.
33
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
AAIPHARMA INC.
Date: August 13, 2002 By: /s/ PHILIP S. TABBINER
--------------- ------------------------------------
Philip S. Tabbiner, D.B.A.
President and Chief
Executive Officer
Date: August 13, 2002 By: /s/ WILLIAM L. GINNA, JR.
--------------- ------------------------------------
William L. Ginna, Jr.
Executive Vice President and
Chief Financial Officer
34
AAIPHARMA INC.
EXHIBIT INDEX
EXHIBIT
NO. DESCRIPTION
3.1 Amended and Restated Certificate of Incorporation of the Company and
Amendment to Certificate of Incorporation dated May 24, 2000, and
Amendment to Certificate of Incorporation dated November 15, 2000
and Amendment to Certificate of Incorporation dated June 27, 2002
3.2 Amended By-laws of the Company (incorporated by reference to Exhibit
3.3 to the Company's Quarterly Report on Form 10-Q for the quarter
ended June 30, 2000)
4.1 Articles Fourth, Seventh, Eleventh and Twelfth of the form of the
Amended and Restated Certificate of Incorporation of the Company
(incorporated by reference to Exhibit 3.1)
4.2 Article II of the Amended By-laws of the Company (incorporated by
reference to Exhibit 3.3 to the Company's Quarterly Report on Form
10-Q for the quarter ended June 30, 2000)
4.3 Specimen Certificate for shares of Common Stock, $0.001 par value,
of the Company (incorporated by reference to Exhibit 4.3 to the
Company's Registration Statement on Form S-1 (Registration No.
333-5535))
10.1 Indenture dated as of March 28, 2002 between the Company, certain of
its subsidiaries and First Union National Bank, as Trustee
(incorporated by reference to Exhibit 10.8 to the Company's
Registration Statement on Form S-1 (Registration No. 333-85602))
10.2 Registration Rights Agreement dated as of March 28, 2002 between the
Company, certain of its subsidiaries, Banc of America Securities
LLC, CIBC World Markets Corp. and First Union Securities, Inc.
(incorporated by reference to Exhibit 10.9 to the Company's
Registration Statement on Form S-1 (Registration No. 333-85602))
10.3 Credit Agreement dated as of March 28, 2002 between the Company,
certain of its subsidiaries, the lenders from time to time party
thereto, and Bank of America, N.A., as administrative agent
(incorporated by reference to Exhibit 10.11 to the Company's
Registration Statement on Form S-1 (Registration No. 333-85602))
10.4 Assignment, Transfer and Assumption Agreement dated as of February
18, 2002 between NeoSan Pharmaceuticals, Inc. and Eli Lilly and
Company (incorporated by reference to Exhibit 2.1 to the Company's
Amendment No. 1 to Current Report on Form 8-K/A dated April 12,
2002)
10.5 Manufacturing Agreement dated as of February 18, 2002 between NeoSan
Pharmaceuticals, Inc. and Eli Lilly and Company (incorporated by
reference to Exhibit 2.1 to the Company's Amendment No. 1 to Current
Report on Form 8-K/A dated April 12, 2002)
35
10.6 aaiPharma Inc. 1997 Stock Option Plan, as amended (incorporated by
reference to Exhibit 10.11 to the Company's Registration Statement
on Form S-1 (Registration No. 333-85602))
10.7 aaiPharma Inc. 2000 Stock Option Plan for Non-Employee Directors, as
amended (incorporated by reference to Exhibit 10.6 to the Company's
Registration Statement on Form S-1 (Registration No. 333-85602))
99.1 Risk Factors
99.2. Statement Regarding Compliance with 18 U.S.C. Section 1350
36